Mankind Pharma Q1 Results FY27: Uniresearch Prediction and Analysis

Mankind Pharma Q1 Results FY27 outlook from Uniresearch is anchored on verified Q4 FY26 actuals and Uniresearch trailing analysis. Uniresearch projects Mankind Pharma Q1 FY27 Revenue Rs 4,444 Cr (+24.5% YoY) and PAT Rs 365 Cr (-18.0% YoY). Prepared by Kunal Singla.

Click Here – Get Free Investment Predictions

Mankind Pharma Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change	Source
Mankind Pharma Revenue (Rs Cr)	3,570	4,444	+24.5%	Uniresearch | Uniresearch trailing analysis
PAT (Rs Cr)	445	365	-18.0%	Uniresearch | Uniresearch trailing analysis
Avg Analyst Target	See screener	12-month view	–	Uniresearch trailing analysis

Mankind Pharma Q4 FY26 Performance

Metric	Q4 FY26 Actual	vs Q1 FY26	Source
Revenue (Rs Cr)	3,443	-3.6%	Screener consolidated
PAT (Rs Cr)	559	+25.6%	Screener consolidated

Analyst Views and Growth Outlook

The Uniresearch trailing analysis projects Mankind Pharma FY27 revenue at +24.5% and profit at -18.0% YoY. Uniresearch applied these growth rates to Q1 FY26 actuals to derive the Q1 FY27 prediction. Q4 FY26 actuals showed Mankind Pharma delivering revenue of Rs 3,443 Cr and PAT of Rs 559 Cr.

Key Watchpoints

Revenue Delivery

Key question: can Mankind Pharma reach Rs 4,444 Cr in Q1 FY27 revenue, representing +24.5% YoY growth over the Q1 FY26 base of Rs 3,570 Cr.

PAT vs Growth Target

Profit performance of Rs 365 Cr (-18.0%) vs the Q1 FY26 base of Rs 445 Cr is the profitability watchpoint for Mankind Pharma in Q1 FY27.

Risks

Revenue Shortfall

Revenue below the +24.5% consensus would indicate sector headwinds or execution delays for Mankind Pharma.

Margin Pressure

Cost increases or margin compression could challenge the -18.0% PAT growth projection for Mankind Pharma in Q1 FY27.

Conclusion

The Mankind Pharma Q1 FY27 Uniresearch projection of Revenue Rs 4,444 Cr and PAT Rs 365 Cr is derived from the Uniresearch trailing analysis. Investors should watch Q4 FY26 actuals as the base, and track Mankind Pharma live on the Univest Screener.

Track Mankind Pharma Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live FY27 alerts.

FAQs on Mankind Pharma Q1 Results FY27

What is Uniresearch’s PAT prediction for Mankind Pharma Q1 Results FY27?

Ans. Uniresearch projects Mankind Pharma Q1 FY27 PAT at Rs 365 Cr (-18.0% vs Q1 FY26 base Rs 445 Cr).

What is the Revenue forecast for Mankind Pharma Q1 Results FY27?

Ans. Mankind Pharma Q1 FY27 Revenue is projected at Rs 4,444 Cr (+24.5% consensus).

What were Mankind Pharma Q4 FY26 actuals for Mankind Pharma Q1 Results FY27?

Ans. Q4 FY26 Revenue Rs 3,443 Cr and PAT Rs 559 Cr.

How many analysts cover Mankind Pharma Q1 Results FY27?

Ans. The prediction uses Uniresearch trailing analysis, avg target Rs 0.

What consensus applies to Mankind Pharma Q1 Results FY27?

Ans. Revenue +24.5% and profit -18.0% (Uniresearch trailing analysis).

What are the main risks to Mankind Pharma Q1 Results FY27?

Ans. Revenue missing +24.5% consensus and PAT pressure vs -18.0% growth target.

What is the Q1 FY26 base for Mankind Pharma Q1 Results FY27?

Ans. Q1 FY26 Revenue Rs 3,570 Cr and PAT Rs 445 Cr.